Cargando…

Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy

BACKGROUND: Trastuzumab (Herceptin), an antagonist to the human epidermal growth factor 2 (HER2) receptor significantly decreases the rates of breast cancer recurrence and mortality by 50%. Despite therapeutic benefits, the risk of cardiotoxicity with trastuzumab ranges from 10–15% when administered...

Descripción completa

Detalles Bibliográficos
Autores principales: Fallah-Rad, Nazanin, Lytwyn, Matthew, Fang, Tielan, Kirkpatrick, Iain, Jassal, Davinder S
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2244612/
https://www.ncbi.nlm.nih.gov/pubmed/18272009
http://dx.doi.org/10.1186/1532-429X-10-5
_version_ 1782150643318784000
author Fallah-Rad, Nazanin
Lytwyn, Matthew
Fang, Tielan
Kirkpatrick, Iain
Jassal, Davinder S
author_facet Fallah-Rad, Nazanin
Lytwyn, Matthew
Fang, Tielan
Kirkpatrick, Iain
Jassal, Davinder S
author_sort Fallah-Rad, Nazanin
collection PubMed
description BACKGROUND: Trastuzumab (Herceptin), an antagonist to the human epidermal growth factor 2 (HER2) receptor significantly decreases the rates of breast cancer recurrence and mortality by 50%. Despite therapeutic benefits, the risk of cardiotoxicity with trastuzumab ranges from 10–15% when administered sequentially following anthraycline chemotherapy. Little is known about the utility of cardiac magnetic resonance (CMR) in the assessment of trastuzumab mediated cardiomyopathy. METHODS AND RESULTS: Between 2005–2006 inclusive, 160 breast cancer patients were identified at a single tertiary care oncology centre. Of the total population, 10 patients (mean age 40 ± 8 years) were identified with trastuzumab induced cardiomyopathy, based on a LVEF less than 40% on serial MUGA or echocardiography. CMR was performed in all patients to determine LV volumes, systolic function and evidence of late gadolinium enhancement (LGE). At the time of diagnosis of trastuzumab induced cardiomyopathy, the mean LVEF was 29 ± 4%. Subepicardial linear LGE was present in the lateral portion of the left ventricles in all 10 patients. CONCLUSION: LGE-CMR is a novel way of detecting early changes in the myocardium due to trastuzumab induced cardiotoxicity.
format Text
id pubmed-2244612
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22446122008-02-15 Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy Fallah-Rad, Nazanin Lytwyn, Matthew Fang, Tielan Kirkpatrick, Iain Jassal, Davinder S J Cardiovasc Magn Reson Case Report BACKGROUND: Trastuzumab (Herceptin), an antagonist to the human epidermal growth factor 2 (HER2) receptor significantly decreases the rates of breast cancer recurrence and mortality by 50%. Despite therapeutic benefits, the risk of cardiotoxicity with trastuzumab ranges from 10–15% when administered sequentially following anthraycline chemotherapy. Little is known about the utility of cardiac magnetic resonance (CMR) in the assessment of trastuzumab mediated cardiomyopathy. METHODS AND RESULTS: Between 2005–2006 inclusive, 160 breast cancer patients were identified at a single tertiary care oncology centre. Of the total population, 10 patients (mean age 40 ± 8 years) were identified with trastuzumab induced cardiomyopathy, based on a LVEF less than 40% on serial MUGA or echocardiography. CMR was performed in all patients to determine LV volumes, systolic function and evidence of late gadolinium enhancement (LGE). At the time of diagnosis of trastuzumab induced cardiomyopathy, the mean LVEF was 29 ± 4%. Subepicardial linear LGE was present in the lateral portion of the left ventricles in all 10 patients. CONCLUSION: LGE-CMR is a novel way of detecting early changes in the myocardium due to trastuzumab induced cardiotoxicity. BioMed Central 2008-01-22 /pmc/articles/PMC2244612/ /pubmed/18272009 http://dx.doi.org/10.1186/1532-429X-10-5 Text en Copyright © 2008 Fallah-Rad et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Fallah-Rad, Nazanin
Lytwyn, Matthew
Fang, Tielan
Kirkpatrick, Iain
Jassal, Davinder S
Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy
title Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy
title_full Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy
title_fullStr Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy
title_full_unstemmed Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy
title_short Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy
title_sort delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2244612/
https://www.ncbi.nlm.nih.gov/pubmed/18272009
http://dx.doi.org/10.1186/1532-429X-10-5
work_keys_str_mv AT fallahradnazanin delayedcontrastenhancementcardiacmagneticresonanceimagingintrastuzumabinducedcardiomyopathy
AT lytwynmatthew delayedcontrastenhancementcardiacmagneticresonanceimagingintrastuzumabinducedcardiomyopathy
AT fangtielan delayedcontrastenhancementcardiacmagneticresonanceimagingintrastuzumabinducedcardiomyopathy
AT kirkpatrickiain delayedcontrastenhancementcardiacmagneticresonanceimagingintrastuzumabinducedcardiomyopathy
AT jassaldavinders delayedcontrastenhancementcardiacmagneticresonanceimagingintrastuzumabinducedcardiomyopathy